4D Molecular Therapeutics (NASDAQ:FDMT) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $38.8, with a high estimate of $40.00 and a low estimate of $36.00. This current average represents a 10.6% decrease from the previous average price target of $43.40.

Understanding Analyst Ratings: A Comprehensive Breakdown

A clear picture of 4D Molecular Therapeutics's perception among financial...